MPR2d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...
PharmExec3d
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome
Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.
Tiny Silicon Valley drugmaker soars on FDA win to treat never-ending hunger
Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...
Pharmaceutical Technology on MSN3d
Soleno wins FDA approval for Prader-Willi hyperphagia treatment
Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...
TipRanks on MSN1d
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone ...
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndromeManagement to host conference call and webcast today, ...
STAT3d
NIH director targets misinformation research as more turmoil rocks health agencies
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
US FDA Approves First Treatment for Rare Genetic Disorder Prader-Willi Syndrome
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic ...
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
PMLive4d
FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome
The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release ...
Soleno Shares Are Up Today: What's Going On?
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...
Soleno Therapeutics price target raised to $81 from $70 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Soleno Therapeutics (SLNO) to $81 from $70 and keeps a Buy rating on ...